Sanofi is to close the Sterling-Midy-Industrie drug research center near Dijon, France, sometime in 1995. The closure is the result of the purchase by Sanofi of Sterling's pharmaceutical business. Many of the staff are likely to be transferred to one of Sanofi's two research centers at Montpelier and Toulouse. Meantime, Sanofi is continuing its divestment policy with an agreement to sell its Perry Ellis line of fragrances to the US company Parlux Fragrances. The Perry Ellis brand has sales of around $19 million per year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze